This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

edited by R. A. Rudick and D. E. Goodkin, 313 pp, with illus, New York, NY, Springer-Verlag NY Inc, 1992.

Robert Herndon, MD, Reviewer
Portland, Ore

Arch Neurol. 1994;51(7):643.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

This compact multiauthored volume provides essential information for anyone who is, or plans to become, involved in clinical trials in multiple sclerosis. In addition, it provides vital information for any neurologist interested in evaluating therapeutic claims for new therapies.

The historical perspective provided by George Ellison is clear, concise, and informative. The chapter on natural history by Dr Goodkin is outstanding, as is the chapter on assessment of outcome by Drs. D. Paty, E. Willoughby, and J. Whitaker.

While the chapter on design and statistical issues is well written, clearly states the requirements for planning studies, and discusses the major statistical issues, this reviewer disagrees strongly with one of their conclusions, namely that "admission to the trial should be restricted to those patients whose Kurtzke Extended Disability Status Scale (EDSS) is 3.5 or less." This conclusion is justified if one accepts the EDSS as the only or principal basis for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?